Innova Captab Valuation

Q: What is the Fair Price of INNOVACAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

INNOVACAP (₹968.75) is trading above our estimate of [[fair value]] (₹729.74)

Is INNOVACAP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INNOVACAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INNOVACAP (₹968.75) is trading above our estimate of fair value (₹729.74)

Significantly Below Fair Value: INNOVACAP is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INNOVACAP?

Key metric: As INNOVACAP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for INNOVACAP. This is calculated by dividing INNOVACAP's market cap by their current earnings.
What is INNOVACAP's PE Ratio?
PE Ratio	46.8x
Earnings	₹1.18b
Market Cap	₹53.32b

INNOVACAP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	31.9x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does INNOVACAP's PE Ratio compare to its peers?

The above table shows the PE ratio for INNOVACAP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	41.4x
AKUMS Akums Drugs and Pharmaceuticals	34.5x	n/a	₹91.4b
WINDLAS Windlas Biotech	31.6x	n/a	₹20.0b
TARSONS Tarsons Products	58.5x	27.7%	₹20.9b
INDGN Indegene	41.1x	18.4%	₹152.0b
INNOVACAP Innova Captab	46.8x	29.7%	₹53.3b

Price-To-Earnings vs Peers: INNOVACAP is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the peer average (41.4x).

Price to Earnings Ratio vs Industry

How does INNOVACAP's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: INNOVACAP is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the Asian Life Sciences industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is INNOVACAP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INNOVACAP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.8x
Fair PE Ratio	41x

Price-To-Earnings vs Fair Ratio: INNOVACAP is expensive based on its Price-To-Earnings Ratio (46.8x) compared to the estimated Fair Price-To-Earnings Ratio (41x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%